Item 1.01 Entry Into a Material Definitive Agreement

On May 10, 2022, a License Agreement (the "License Agreement") was entered into by and between Jawaharlal Nehru Centre for Advanced Scientific Research ("JNCASR"), Bengaluru ("Licensor") and Hamsa Biopharma India Private Limited, Delhi ("Licensee"). As a result of the License Agreement there was a transfer of rights of a proprietary technology and know-how of certain patents and patent filings relating to small molecule inhibitors with a naphthalene monoamide scaffold ("NMI Compounds").

The NMI Compounds, to which we have the rights to, can potentially, but there can be no assurance thereof, ameliorate in vitro and in vivo amyloid induced neurotoxicity, which are prospective candidates to treat certain nervous system disorders in humans, including Alzheimer's Disease; and/or may have other pharmacological or non-pharmacological benefits and applications.

The JNCASR is an autonomous institution under the Department of Science and Technology, Government of India, an institution deemed to be a University, having its office at Bangalore Karnataka, India. Hamsa Biopharma India Private Limited is a wholly owned subsidiary of India Globalization Capital Inc. (NYSE:IGC).

Item 9.01 Financial Statement and Exhibits.





(d) Exhibits.



Exhibit No. Description
              License Agreement entered into on May 10, 2022 by and between Jawaharlal
10.1        Nehru Centre For Advanced Scientific Research, Bengaluru and Hamsa
            Biopharma India Private Limited, Delhi.1
104         Cover Page Interactive Data File (formatted as Inline XBRL)




  1 Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of
    Regulation S-K because they are both (i) not material and (ii) the type that
    the registrant treats as private or confidential. A copy of the omitted
    portions will be furnished to the SEC upon its request.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses